Abstract: Chronic kidney disease (CKD) is a worldwide disease with higher prevalence, and makes a tremendous burden to the societies. Hyperkalemia is a common and  life-threatening electrolyte imbalance complication, and is closely related to the higher all-cause and cardiovascular mortality of this disease. Meanwhile, the use of renin-angiotensin-aldosterone system inhibitor (RAASi) in CKD patients with cardiovascular disease aggravates the risk of hyperkalemia, which may limit the use of RAASi in this particular population. Therefore, appropriate use of potassium-binding agents is of great significance to improve the overall prognosis and to relieve their economic burden. This review aims to summarize the application of patiromer and sodium zirconium cyclosilicate (SZC) in CKD patients in order to provide references for further studies.

Key words: Chronic kidney disease, Hyperkalemia, Patiromer, Sodium zirconium cyclosilicate